Black men may have an increased risk of prostate cancer progression on active surveillance

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.

Key clinical point: The potential association between increased progression risk and active surveillance among Black men with prostate cancer is not strong enough to discourage active surveillance in this population.

Major finding: The overall relative risk of prostate cancer progression among Black men on active surveillance was 1.62; this effect decreased over time, with a relative risk of 1.29 for studies after 2019.

Study details: The data come from a meta-analysis of 8 prospective and 4 retrospective studies of men with Grade Group 1 or 2 prostate cancer.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Vigneswaran HT et al.  Prostate Cancer Prostatic Dis. 2021 Jul 8. doi: 10.1038/s41391-021-00425-1.